Jefferies says Denali to benefit by data from Roche's Alzheimer drug delivery system

Denali Therapeutics

25/10/2023 19:53

** Shares of Denali Therapeutics  DNLI.O  up ~1% to $19.84
    ** Roche Holding  ROG.S  presented data from early-to-mid
stage studies of Alzheimer's drug being delivered using its
"Brain Shuttle" technology at Clinical Trials on Alzheimer's
Disease conference
    ** "Brain Shuttle" technology is aimed at increased
penetration of large molecules based drug such as antibodies
into the brain
    ** Roche's data, which showed significant reduction in
amyloid, is encouraging and could be positive for similar or
enhanced version of "Brain" shuttle being developed DNLI - said
the brokerage Jefferies
    ** The use of the technology for delivery of the drug also
produced minimal ARIA, which is a type of brain swelling caused
due to the treatment-related adverse side effect  
    ** Alzheimer's is a progressive, degenerative disorder of
the brain and the most common form of dementia among the elderly
    ** Including session gains, DNLI's shares are down ~29% YTD 

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com))